GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis Post-Market Clinical Follow-Up (PMCF) Observational Registry (RE-PROVE)

This is a prospective, multicenter, observational registry to collect real world data of the Reduced Profile GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis (Reduced Profile VBX Stent Graft-BXB) device.

The registry population will include subjects presenting with clinical conditions consistent with the BXB device indications for use and in accordance with standard of care. The following subject cohorts will be included in the registry:

* De novo or restenotic lesions in the iliac arteries including lesions at the aortic bifurcation \[Aortoiliac occlusive disease (AIOD)\], * De novo or restenotic lesions in the visceral arteries \[Visceral artery occlusive disease (VAOD)\], * Isolated visceral, iliac, and subclavian artery aneurysms \[IAA\], or * Traumatic or iatrogenic vessel injuries in arteries that are located in the chest cavity, abdominal cavity, or pelvis (except for aorta, coronary, innominate, carotid, vertebral, and pulmonary arteries) \[Arterial Injury (AI)\].

To satisfy a key objective of the PMCF plan, clinical data will be collected in other indications outside of those listed above (Other cohort).

Approximately 24 clinical investigative sites in Europe, will participate in this registry. 240 subjects will be implanted in this study with a limit of 48 subjects treated / implanted per site. If a site reaches 48 subjects, enrolment will be closed for that site. All subjects will be followed through 12 months (1 year) post-procedure per standard of care. Quality of Life questionnaires will also be collected for all follow-up visits.

• Primary patency for patients treated in Aortoiliac Occlusive Disease (AIOD) through 1 year follow-up [Срок оценки: from the time of the index procedure up to 365 days (±window, between days 335 and 455)]
• Freedom from major amputation of the BXB device treated limb for patients treated in AIOD [Срок оценки: from the time of the index procedure up to 365 days (±window, between days 335 and 455)]
• Primary patency for patients treated in Visceral Occlusive Disease (VAOD) [Срок оценки: from the time of the index procedure up to 365 days (±window, between days 335 and 455)]
• Survival for patients treated in VAOD [Срок оценки: from the time of the index procedure up to 365 days (±window, between days 335 and 455)]
• Freedom from reintervention through 1 year follow-up for patients treated in Isolated Artery Aneurysm (Subclavian, Visceral, Iliac) [Срок оценки: from the time of the index procedure up to 365 days (±window, between days 335 and 455)]
• 30 Day Mortality for patients treated in IAA [Срок оценки: from the time of the index procedure through 30 days]
• Treated vessel primary patency through 1 year follow-up for patients treated Trauma or Iatrogenic Vessel Injury [Срок оценки: from the time of the index procedure up to 365 days (±window, between days 335 and 455)]
• Device-related adverse events (i.e. thrombosis) for patients treated in Trauma or or Iatrogenic Vessel Injury [Срок оценки: from the time of the index procedure up to 365 days (±window, between days 335 and 455)]